A study to assess outcomes of eculizumab discontinuation and monitoring protocol in a prospective cohort of patients with atypical hemolytic uremic syndrome
Latest Information Update: 08 Jan 2021
At a glance
- Drugs Eculizumab (Primary)
- Indications Atypical Haemolytic Uraemic Syndrome
- Focus Therapeutic Use
- 08 Jan 2021 New trial record
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology